Furthermore, since the antitumour efficacies of PD-1/PD-L1 checkpoint inhibitors and other markers have already been established, studies can now look at using approved and marketed drugs that are not used for cancer treatment but are able to modulate the function of these checkpoint inhibitors, thus repurposing them to improve therapy for solid cancers. This evidence concerns the gene PDCD1 and cancer.